After Carlsbad, CA-based Verdezyne disclosed last month that it plans to raise more than $15 million in venture funding, I arranged to sit down with Damien Perriman, the company’s vice president of business development.

As it turns out, the startup that was founded in 2005 as CODA Genomics has essentially re-engineered itself over the past 18 months. The company overhauled its core business strategy, recruited a new CEO, E. William Radany, along with a new management team, changed its name, and moved its headquarters from Orange County to Carlsbad, CA, about 28 miles north of San Diego. In changing its name to Verdezyne, the company created an identity that is better aligned with its revised focus on the “green design” of biofuels and industrial chemicals.

The company initially was focused on technology spun out from UC Irvine that used specialized computer algorithms to design synthetic DNA. The company offered its services in Computationally Optimized DNA Assembly, or CODA, to help drug discovery teams at pharmaceutical customers like Eli Lilly and Genentech design synthetic genes that could be used to maximize the production of certain proteins for their biotech drug manufacturing processes.

Perriman, who joined Verdezyne in February, tells me, “Our investors made a decision in 2008 that we could make a lot more money by doing the production ourselves.”

With its extensive experience in computational biology and bioinformatics, Verdezyne saw the value in creating high-diversity libraries of genes, so that various genes could be inserted into fast-dividing yeast cells (and other micro-organisms), essentially programming the microbes to produce enzymes it would not otherwise produce. Verdezyne landed a federal grant last month to help build out its genomic library.

“We prefer to work with yeast,” Perriman says, “but we can work with any fungi or bacterial organism.”

The company, which now has 26 employees, has identified three primary markets for its technology.

The first and most obvious target is an …Next Page »

Comments | Reprints | Share:        

We hope to make this a regular feature in our Xconomy cities. It’s a look at small financings of private companies in tech, life sciences, and cleantech. These are deals in the roughly $100,000 to $1 million range, and they’re increasingly where the action is for local entrepreneurs, yet they’re often harder to track than the bigger deals we tend to report on.

And there were at least 12 of these smaller financings in the Northwest in October (see table below), according to ChubbyBrain, a New York-based information services company tracking VC, angel, and other investments in private companies. ChubbyBrain gets its data from regulatory filings, user submissions, and other sources, and this is the second monthly installment of “under the radar” deals in the Seattle area (you can see the previous deals for September here). The data didn’t include the investors or the stage of financing.

A few quick observations: Like the previous month, most of the financings were in Washington (7 out of 12), but a significant number (5) were in Oregon. Most were equity deals (7), with the rest (5) being debt financings. The majority of financings (9) were in software, Internet, or tech, while a much smaller number (3) were in life sciences and healthcare, and no cleantech or energy deals made the list.

If nothing else, these lists are a cool way to hear about emerging startups we otherwise wouldn’t know about. For example, I’ve heard of Teranode, Nearlyweds, and 1000Museums before, but Zapproved and Intellisist are completely new to me.

Here are the 12 “under the radar” deals from last month:

Comments (1) | Reprints | Share:        

Aptera, the sleek carmaker backed by Google and Idealabs, didn’t respond to my inquiry earlier this week about reports of an internal split in which founders Steve Fambro and Chris Anthony had left the company. But in an online report published today by The San Diego Union-Tribune, Aptera officials rejected accounts that Fambro and Anthony were ousted in a boardroom showdown.

The company’s status is a keen issue to some 4,000 people, including celebrities Tom Hanks, Robin Williams, and Shaquille O’Neal, who have put down $500 deposits to be the first to buy one of the three-wheel, two-seater vehicles. The Aptera 2e, the company’s first production vehicle, resembles a wingless plane and is expected to cost between $25,000 and $40,000. Aptera is based in Vista, CA, about 30 miles north of San Diego.

Citing a statement issued by Aptera CEO Paul Wilbur, the Union-Tribune says the carmaker had to adjust its production schedule “to align with financing realities.” Instead of producing its first fuel-efficient model in the fall of 2009, as Aptera announced at the beginning of this year, Wilbur says the company will complete its first vehicles in 2010. About 10 of Aptera’s 40 employees have been laid off.

The company, which has raised at least $27.5 million from Google, Idealabs, and other venture investors, is seeking additional funding, according to Popular Mechanics. Aptera says it also intends to resubmit its application for a $75 million loan from the Department of Energy’s Advanced Technology Vehicles Manufacturing Incentives Program.

Aptera says co-founders Fambro and Anthony were not asked to leave. Fambro remains on the board, but has taken a leave of absence from the company until next year. Anthony is now the CEO of Flux Power, a startup in the San Diego area that is developing battery-management systems. In another online account published by Popular Mechanics magazine, Fambro also voiced his continuing support for CEO Wilbur.

Comments (2) | Reprints | Share:        

As startups developing next-generation biofuels emerge in San Diego, Boston, and elsewhere, a business model for rapidly expanding to commercial-scale operations already can be found in the biotech industry, experts said yesterday. The premise of presentations organized by Biocom, San Diego’s life sciences industry group, is that collaborations being formed between biofuel startups and big energy are comparable to the partnerships formed between biotech startups and big pharmaceutical companies.

Biofuels development partnerships will be crucial to meeting renewable fuel standards that the federal government set in the Energy Independence and Security Act of 2007. Wain Fishburn, a founding partner of the Cooley Godward law firm’s San Diego office, said the standards require the U.S. biofuels industry to increase its production fourfold—from 9 billion gallons in 2008 to 36 billion gallons in 2022. Fishburn, who introduced the speakers at the Biocom event, said the ability to meet the federal goal depends on a variety of factors, including the ability to lower the cost of biofuels to be competitive with petroleum-based crude, and the scalability of feedstock, production facilities, distribution, and related infrastructure.

But what it really comes down to, as Verenium (NASDAQ: VRNM) executive William Baum told the audience, is capital.

Baum, who became Cambridge, MA-based Verenium’s executive vice president of business development in 2007 (following the 2006 merger of San Diego’s Diversa and Cambridge’s Celunol) said the need for capital was the theme he heard “over and over again” during a recent meeting that focused on the biofuels industry. “We’ve got hundreds of biofuel companies that are trying to get to the next stage. If you don’t have a big brother with deep pockets, like a BP, Exxon, Shell, or a Chevron, it’s going to be very difficult.”

A number of partnerships already have been established between biofuels startups and major energy conglomerates, Fishburn noted. He listed the following collaborations:

—BP, the London-based global energy conglomerate, has formed two strategic partnerships with Verenium, which has been developing technology to produce cellulosic ethanol using proprietary microbes to accelerate the breakdown of non-edible, high-cellulose plant material into ethanol. Baum described the first collaboration, announced in August 2008, as a technology joint venture for IP. (BP agreed to put up $90 million to develop “low-cost, environmentally sound cellulosic ethanol production facilities in the United States.”) Through a second deal announced nine months ago, BP agreed to provide an additional $45 million and to form a …Next Page »

Comments (2) | Reprints | Share:        

Drug development programs got extended at two San Diego life sciences companies, while others had some good news on the fund-raising front. We wrap it all up for you here.

—Fate Therapeutics, a startup working to supply “industrialized” stem cells for the pharmaceutical industry without using embryos, said it raised $30 million in venture capital. That brings the total amount raised by the San Diego-based company to about $50 million since its inception two years ago.

—Cadence Pharmaceuticals (NASDAQ: CADX) said the FDA has delayed its review of the San Diego company’s intravenous pain reliever by three months, to Feb. 12. Cadence provided additional data to the FDA after an advisory panel raised concerns about liver damage from excessive doses of acetaminophen. But Cadence said it remains confident it will win FDA approval of its drug, which contains acetaminophen.

—Carlsbad, CA-based Isis Pharmaceuticals (NASDAQ: ISIS) and its Big Pharma partner, Genzyme (NASDAQ: GENZ), have extended the timeline for their much-anticipated cholesterol-lowering drug by nearly a year. The companies reported encouraging results from a clinical trial, but noted that four out of 34 patients saw their liver enzymes increase to three times normal, a sign of potential liver damage. The companies plan to tinker with the dose of the injectible drug in future trials.

—San Diego-based NextImage Medical, a developer of a Web-based system for scheduling and managing diagnostic imaging services, reporting raising $5 million in a venture round led by Chrysalis Ventures of Louisville, KY.

—San Diego-based Altair Therapeutics, a company developing inhalable drugs to block inflammatory proteins involved in asthma and other respiratory diseases, has closed on the second part of a Series A venture financing, bringing the total amount raises this year to $17 million.

—San Diego-based Cyntellect, which makes work stations used by biotechs for cell analysis, purification, and processing, raised $15.5 million so far in a secondary round that aims to raise a total of $18.6 million, according to a recent regulatory filing.

—GenVault, a Carlsbad, CA-based company that markets dry-storage technologies that allow scientists to store biological samples at room temperature, said it expects to break even by the end of next year. The startup has raised about $32 million so far.

Comments | Reprints | Share:        

San Diego’s NextImage Medical, Inc., which has developed a Web-based system for scheduling and managing diagnostic imaging services, says it has raised $5 million in Series A funding in a round led by Chrysalis Ventures of Louisville, KY. Liz Griggs founded NextImage Medical last year as a way to provide high-quality, low-cost radiology services, either through insurers, self-insured employers, or direct-to-consumer. A statement from NextImage Medical says Griggs previously was the founder of New Jersey-based One Call Medical, a radiology preferred provider organization (PPO) that was sold in 2003 for $115 million.

Comments | Reprints | Share:        

Just when I thought venture deals, especially for software and tech companies, had headed south for the winter (or longer), the Northwest erupted with a slew of financings in the past week.

—But first, some serious biotech. Kirkland, WA-based OVP Venture Partners led a $30 million Series B round for Fate Therapeutics, a San Diego-based stem cell company with ties to the University of Washington, as Luke reported. Existing investors Arch Venture Partners, Polaris Venture Partners, and Venrock Associates also participated in the funding, as well as three strategic corporate investors—Astellas Venture Management and Genzyme Ventures were named.

—Seattle-based DocuSign, a maker of software to automate and control the process of electronic signatures, received a strategic investment from Second Century Ventures, the VC fund of the National Association of Realtors. The funding amount was undisclosed, but the money will be used to accelerate and extend DocuSign’s efforts with real estate customers.

—Beaverton, OR-based Avnera pulled in an $8 million equity round from undisclosed investors, according to a regulatory filing. The company’s previous investors include Bessemer Venture Partners, Redpoint Ventures, Jafco Ventures, Intel Capital, and DAG Ventures. Avnera was founded in 2004, and designs novel chips for wireless audio applications.

—Seattle stealth startup Doxo raised $5.25 million in equity financing, according to a regulatory filing and media reports. The investors were not disclosed, but David Feinleib of Mohr Davidow Ventures was listed on the SEC form as a director.

—Bellevue, WA-based Enroute Systems, a developer of software that helps companies manage their parcel-shipping logistics, closed a Series A funding round worth $810,000 from Keiretsu Forum, Zino Society, Puget Sound Venture Club, and angel investors. Next up, Enroute is looking …Next Page »

Comments | Reprints | Share:        

Paul Wilbur, a Detroit auto industry veteran who was named CEO of Carlsbad, CA-based Aptera 14 months ago, gave no indication of internal turmoil at the futuristic car’s headquarters when he appeared last week at an event sponsored by Cleantech San Diego.

But as Darryl Siry reports today on Wired’s Autotopia blog, a prolonged power struggle that pitted Aptera founders Steve Fambro and Chris Anthony against Wilbur and Aptera board members apparently came to a head in recent weeks. Wired says rumors about the founders’ departure, as well as layoffs amid financial difficulties, began appearing last week on the Aptera Forum, an online message board for Aptera car enthusiasts. Aptera did not immediately respond to an e-mail query seeking the company’s response to the reports. According to Wired, the company says it’s slowing down its burn rate while waiting for the Department of Energy to review its loan application, and maintains that its relationship with Fambro and Anthony remains positive.

Fambro, who founded Aptera about six years ago, has previously said his aim with the company was to build a safe and comfortable passenger vehicle that was more fuel-efficient than anything else on the road. The company says the prototype of its aerodynamic pod-shaped, three-wheel vehicle gets 230 miles to the gallon.

Aptera raised about $24 million roughly 18 months ago from investors that include Google and Idealab. CEO Wilbur told me last year that the company was having no trouble attracting additional funding, but the Wired blog reports that additional funding has in fact been difficult to secure during a drawn-out battle over which course the company should be steering.

Comments | Reprints | Share:        

San Diego’s Global Analytics Holdings says it has raised $10 million of a targeted $14 million round that consists of equity investments, options, and rights to securities, according to a recent regulatory filing. The company provides consulting services for business customers and specializes in developing software for statistical analysis, predictive modeling, and neural networks.

The filing indicates the capital is being raised in connection with a merger, acquisition, or exchange offer, but founding CEO Krishna Gopinathan did not respond to a call or e-mail seeking further information. According to the Global Analytics website, Gopinathan was the primary inventor of Falcon Fraud Manager, a neural-network technology developed at San Diego-based HNC Software (now part of Fair Isaac) that is used to protect most credit cards worldwide.

Global Analytics has been operating at least five years and has more than 100 employees, according to its website. A number of key executives at Global Analytics, including the executive vice president of analytics, vice president of products, and vice president of software development, are former HNC employees.

Last year, Global Analytics named Larry Rosenberger, the former CEO of Minneapolis, MN-based Fair Isaac, to its board of directors. The company also noted that Rosenberger and his wife Diane invested in the San Diego startup. Peter Rip, a general partner at San Francisco’s Crosslink Capital, also is on Global Analytics’ board, although Crosslink does not identify Global Analytics as a portfolio company.

Global Analytics also has formed a strategic partnership with Hewitt Associates, the Illinois-based human resources and outsourcing firm, and has been working on what it calls “the objective quantification of the value of human capital investments.” The company says it has been working with Hewitt in recent years to pioneer development of comprehensive models that tie such human resources metrics as talent attraction, retention, and engagement to shareholder value, creating what Hewitt calls its Human Capital Foresight.

Comments | Reprints | Share:        

Seattle-based DocuSign announced today it has received a strategic investment from Second Century Ventures, the VC fund of the National Association of Realtors. The amount was undisclosed, but the cash will be used to speed up and extend DocuSign’s efforts with residential and commercial real estate customers. DocuSign was founded in 2003 and makes software to automate and control the process of electronic signatures.

Comments | Reprints | Share:        

San Diego serial entrepreneur Michael Robertson is going to have to find something else to do now that Gizmo5, the VoIP (voice-over-Internet-protocol) company he founded in 2003, has become part of a certain search giant to the north. We have that news and more.

—Google confirmed that it’s buying San Diego-based Gizmo5, a six-year-old company that provides Internet-based calling software for mobile phones and computers. The service will become part of the Google Voice number-unification service. Google did not disclose the purchase price, which media reports put at about $30 million. Gizmo5’s 6 million users will still be able to use the service, according to a statement. But Google is suspending new Gizmo5 signups, and existing users can no longer sign up for a call-in number.

—Platformic, a Web-based startup that enables customers to create and manage their own websites, said it is adding social media capabilities. The two-year-old San Diego-based company, which has targeted broadcast companies, says its expanded software-as-a-service product will help a broadcaster’s audience share photos, create their own user profiles, and create personal blogs on the broadcaster’s Platformic-powered website.

—Qualcomm’s No. 2 executive opened a regional mobile technology conference in San Diego by providing an overview of steps the chipmaking giant is taking to help ease the pressure on wireless network bottlenecks as mobile data traffic soars. Qualcomm (NASDAQ: QCOM) Chief Operating Officer Len Lauer told the 3G CDMA Americas Regional Conference that in the year 2014, worldwide mobile data traffic in one month will exceed mobile data traffic for all of 2008.

—Technology innovations that help companies optimize their profitability will likely lead to the next wave of analytics-based software startups, according to Stephen Coggeshall of San Diego-based ID Analytics. Another hot area will be analytics that can help forecast consumer behavior, said Coggeshall, who was participating in a discussion about new opportunities in analytics during the San Diego Software Industry Council’s annual forum on analytics.

—Israel’s Panoramic Power won $250,000 and became the first winner of the top QPrize, the incentive prize competition launched earlier this year by Qualcomm Ventures. Panoramic Power is developing energy-monitoring wireless technology that enables a company or institution to deploy so-called “smart grid” technologies within their existing facilities.

—The San Diego-based Cannon Power Group said is getting $19.4 million in federal renewable energy grants to help fund construction of a giant wind farm in eastern Washington state, about 110 miles east of Portland, OR. The $1 billion Windy Point/Windy Flats project is expected to generate enough electricity for 250,000 homes.

Comments | Reprints | Share:        

Early-stage tech financings are still chugging along, it seems. On the heels of yesterday’s news of a $5.25 million financing of Seattle stealth startup Doxo, I checked in with Keith McCall of Bellevue, WA-based Enroute Systems, a maker of parcel-shipping management software, to hear the latest on his company’s recent financing.

McCall, the company’s founder and CEO, says Enroute has closed an oversubscribed Series A round worth a total of $810,000. That includes more than $500,000 from Keiretsu Forum Northwest earlier this year, and a new investment (as of October) from W.R. “Ford” Smith, the founder of PetSmart. Other investors include Zino Society and Puget Sound Venture Club. (The Series A round also includes $60,000 that Enroute won in Zino Society’s investment forum this fall.)

Enroute makes a Web-based software platform that helps businesses choose the cheapest and fastest delivery service—international, national, or regional carriers—to ship their packages. McCall says the software reduces companies’ shipping costs by about 30 percent.

The startup has moved into new 4,500-square-foot digs in Bellevue—near the Burgermaster and Microsoft’s original offices—as of the start of November. It is now up to a dozen employees and has signed more than 50 business customers, including Zumiez, Natural Partners, Renton Western Wear, Theo Chocolate, BikeWagon.com, and Lumber Liquidators.

McCall, who previously founded Seattle-based e-mail and communications management firm Azaleos, says he expects Enroute to be profitable in the first half of next year, and is now focused on expanding its customer base.

With that in mind, he is already getting ready to raise more money. “For those investors who would like to join our existing angel investors today, we are immediately opening a $500K convertible note, which we anticipate converting to a Series B offering in 2010,” McCall says. He adds that the next formal capital raise “is targeted as a $3 million Series B.”

McCall says that next financing round will be focused on expanding the company’s shipping-management services to Asia and Europe. “We’re interested in continuing our momentum,” he says. “There’s huge opportunity for us to significantly reduce cost for businesses of all sizes.”

Comments | Reprints | Share:        

San Diego-based Cyntellect , which makes work stations used by biotechs for cell analysis, purification, and processing, has raised $15.5 million so far in a secondary round that aims to raise a total of $18.6 million, according to a recent regulatory filing.

Cyntellect says its instruments are used in life sciences research, biopharmaceutical production, stem cell research, and drug discovery. The company says its cytometers provide scientists with rapid, high-quality imaging and analysis of cells in every well of a 384-well microplate array. Cyntellect says its instruments can scan an entire well while maintaining consistent illumination for accurate cell identification from the center to the well edge. The company’s product line also includes an automated system for cultivating cell lines used in biopharmaceutical manufacturing.

The current venture round consists of equity investments and convertible warrants, according to the filing. Cyntellect was founded in 1997, and earlier investors in the company include Bru II Venture Capital Fund, Iceland Genomics Ventures, Sigma-Aldrich, Sumitomo, and Third Security, according to VentureWire.

Comments | Reprints | Share:        

[Updated 11/18/09, see below] This post is about how to get a better deal from VCs investing in your first round of financing. It is also about how to make the deal into a win-win. The idea for the post came from an exchange with @bakespace about some of the resources for entrepreneurs on FastIgnite.

This is About Series A Deals

Seed investments can be all over the map in terms of size ($50K – $1M+), structure (convertible debt or common/preferred equity), valuation, and investor rights. It’s hard to make generalizations about seed deals.

First-money-in Series A deals, on the other hand, tend to be much more cookie-cutter. Before we talk about why this is the case, let’s put a rough definition around the types of Series A financings I’m referring to:

• Not much has been raised previously—at most a few hundred thousands and ideally nothing.

• The product has not been (fully) built.

• The size of the round is at least $3M but preferably larger.

• You are talking to professional VCs with funds > $100M.

These deals tend be cookie-cutter because they are driven more by the cap table (the list of shareholders in a startup and how many shares they own) than by what the company might be worth independently.

What is Your Startup Worth?

This is a question entrepreneurs think a lot about. They come up with all kinds of arguments for justifying their notion of value pre-funding. The trouble is, most of the arguments are bogus because they miss an important point: a company that needs several million dollars today to build a business is not worth much at all without the dollars.

Say the goal is to stick a flag on top of Everest. You are a great alpinist but you have no money for the expedition. Your friend Bob loves what you do, happens to be excited about you climbing Everest and has tons of dough. Which is more important? Your ability to climb or the financing? You ability to climb is certainly scarcer and hence commands a certain premium, but in the end it’s a partnership. Money without an alpinist can’t get to Everest. An alpinist without funding can’t get to Everest either. It is the combination of the scarce talent (climbing) and the resources to make this talent productive (the dollars) that creates the value.

The Series A Valuation Process

What this means for your Series A deal is that, to a large extent, the value of your company is going to be reverse-engineered from the cap table. Here is how this works:

1. You and your investors agree you need $X ($3M, for example)

2. The investors want to own a certain percentage post-financing (I%) (2 x 20% = 40%, for example if two VCs are syndicating the deal)

3. The post-money valuation is now $X/I% or $3M/40% = $7.5M

4. You negotiate the size of the option pool (P%) (25%, for example)

5. Your true pre-money valuation (what the founders’ stake is worth) is $X*[(1-I%-P%)/I%] or $2,625,000.

There are two things to notice about this process. First, at no point did it require justifying the value of the startup. Second, the margin for negotiation is somewhat limited as (a) the option pool size should be budget-driven and (b) most investors, rightly or wrongly, are pretty set on the percentage ownership they require. (The reasons for this have to do with the business models of venture firms—which are too complicated to cover here.)

Without meaningful deal competition, you’ll be unlikely to affect the investor(s) target ownership percentage. So if you really want to get your VCs to take a lower percentage, you’ll have to work a lot harder to generate interest from multiple firms. Either that, or you’ll have to …Next Page »

Comments (17) | Reprints | Share:        

Some San Diego life sciences companies reported a burst of new financing, while embattled Sequenom told investors it’s trying to conserve its available cash. Here’s our rundown of the latest highlights:

—San Diego’s Trius Therapeutics, a venture-backed biotech developing a new antibiotic for treating acute and life-threatening bacterial infections, disclosed plans to raise as much as $86 million in an initial public stock offering. With additional funding, the company will proceed to Phase 3 clinical trials of torezolid, which Trius describes as a second-generation successor to linezolid, the Pfizer antibiotic known as Zyvox.

—Life Technologies (NASDAQ: [[ticker: LIFE]]), the Carlsbad, CA-based provider of biotech instruments and lab supplies, agreed to acquire Woburn, MA-based BioTrove, which has developed a high throughput gene expression and genotyping analysis system.

— SpectraScience, the San Diego medical device maker, has raised more than $4.3 million through a private placement that combines preferred shares and warrants. SpectraScience (OTCBB: [[ticker: SCIE]]) CEO Jim Hitchin told Bruce the offering closes a $5 million round the company began earlier this year.

—PaxVax, a San Diego startup backed by Seattle’s Ignition Capital, has raised $2 million of a planned $6 million investment round. The biotech founded in early 2007 is developing a new type of vaccine that is administered as oral tablets and avoids much of the requirements that conventional vaccines require.

—Sequenom, San Diego’s embattled diagnostics company, said it expects to end the year with $39 million in cash—but that’s not enough to get through 2010 without raising funds or slowing spending. In April, Sequenom (NASDAQ: [[ticker: SQNM]]) disclosed that it had “mishandled data” from a prenatal Down syndrome diagnostic test, indefinitely postponing that product launch.

Comments | Reprints | Share:        

San Diego-based Qualcomm (NASDAQ: QCOM) says Panoramic Power, a wireless sensor startup based in Kidron, Israel, is the winner of the first QPrize, the incentive prize competition launched earlier this year by Qualcomm Ventures. Panoramic Power has developed energy monitoring wireless technology that enables a company or institution to deploy Smart Grid technologies within their existing facilities. Panoramic Power, which previously won $100,000 as a QPrize regional winner, was awarded another $150,000 and the opportunity to compete in a global business plan competition held at the Mobile World Congress in Barcelona, Spain.

Comments | Reprints | Share:        

The San Diego-based Cannon Power Group says it has received $19.4 million in federal renewable energy grants to help fund construction of a 400-megawatt wind farm in Klickitat County, WA, about 110 miles East of Portland, OR. Total investment in the project will be more than $1 billion. When completed, the Windy Point/Windy Flats project will be one of the largest wind farms in the nation, producing enough electricity for more than 250,000 homes per year. The project power has been designated for use by California municipalities.

Comments | Reprints | Share:        

PaxVax, a San Diego startup backed by Seattle’s Ignition Capital, has raised $2 million of a planned $6 million investment round, according to a document filed Friday with the Securities and Exchange Commission.

The biotech was founded in early 2007 to develop new oral vaccine technology based on a common cold virus called the adenovirus. The company says its vaccine, which is administered as oral tablets, avoids much of the requirements that conventional vaccines require—including cold storage for the vaccine itself and inoculation by qualified medical personnel. PaxVax says its oral tablets can be stored and distributed at room temperature, and are self-administered.

PaxVax says its vaccines also can be produced in large quantities and at record speed and low expense compared with traditional vaccines derived from egg culture. The company also says an oral vaccine may yield a more robust immune response than traditional vaccines.

The biotech was co-founded by Ken Kelley, who has worked in biotechnology for more than 25 years, including such companies as IntraBiotics Pharmaceuticals of Palo Alto, CA, and Integrated Genetics (acquired by Genzyme), and with such venture capital firms as K2 BioVentures and Latterell Venture Partners, according to the PaxVax website.

PaxVax’s board includes Ignition Capital operating partner Rennie Coit, who represents the Seattle VC firm at PaxVax. A pediatrician who got his medical degree at UC San Diego, Coit previously worked as a strategic planning consultant to clients that included academic medical centers, health insurance proviers, medical research organizations and global health providers. He also served as the chief operating officer of the University of Washington Medicine Neighborhood Clinics.

Comments | Reprints | Share:        

It was a busy week for local technology news.

—Two teams from San Diego and a third from Northern California demonstrated their development of advanced chemical sensor prototypes that are tiny enough to be found inside ordinary cell phones. The U.S. Department of Homeland Security is funding the Cell-All program, with a goal of basically creating an anti-terrorism app for cell phones that would enable authorities to crowd-source chemical detection.

—MaxLinear has filed for its initial public stock offering. The Carlsbad, CA-based fabless chipmaker, which specializes in designing semiconductor-based television receivers, intends to raise about $100 million through its IPO. The market may be de-frosting a bit, with 47 IPOs so far in 2009, compared with 45 last year, and 272 in 2007.

—ProQuo, a San Diego-based Web 2.0 company that was founded in 2007, was quietly shut down after taking in a total of $15 million in venture capital from Menlo Park, CA-based Draper Fisher Jurvetson and San Diego-based Mission Ventures. ProQuo was never able to validate its business model; its website offered consumers a way to remove their names from mass-mailing lists for free, and the company planned to sell its optimized lists back to mass marketing companies.

—San Diego’s wireless industry group, CommNexus, celebrated the opening of EvoNexus, its free high-tech incubator, by announcing the selection of three more startup companies: EcoATM, MicroPower Technologies, and TetraVue. CommNexus CEO Rory Moore says EvoNexus is believed to be the first incubator that is completely free for startups—that is, it doesn’t even require an equity stake in participating companies, as most incubuators do.

—Jitterbug, the San Diego wireless provider that puts an emphasis on simplicity, has acquired MobiWatch, a Waltham, MA-based startup developing mobile personal emergency response services. A regulatory filing shows that Jitterbug’s parent, GreatCall, provided 630,000 shares of common stock to MobiWatch and its shareholders in a deal valued at $107,100.

—San Diego-based Networkfleet is using its technology to help companies that operate fleets of vehicles go green by monitoring engine emissions and ensuring that vehicles are operating efficiently. Co-founder Diego Borrego told me the company also expects to be a player as consolidations sweep through the fleet tracking industry.

—EcoDog, a Vista, CA, cleantech startup that has developed a device that helps homeowners sniff out savings in their electric utility bill, was named best of show at GadgetFest, the annual fall competition sponsored by CommNexus, the San Diego wireless industry group. EcoDog founding CEO Ron Pitt won over the crowd when he declared, “My product is the only product up here tonight that saves you more money than it costs.”

—San Diego-based cleantech startup EESG is looking to raise $1.2 million to expand the 10-employee company’s sales staff, purchase inventory, and ramp up public relations and marketing. The company’s founders told me they have raised about half so far, including $300,000 from Longboard Capital Advisors, a green investment firm based in Santa Monica, CA.

Comments | Reprints | Share:        

MaxLinear, a fabless RF chipmaker based in Carlsbad, CA, filed a registration statement today for an initial public stock offering, marking only the second IPO in the San Diego area since Bridgepoint Education made its debut on the New York Stock Exchange in April. About 45 IPOs have taken place nationwide so far this year.

Eight semiconductor industry veterans founded MaxLinear in 2003. The company specializes in designing highly integrated, CMOS (Complementary metal–oxide–semiconductor) chips, and has had notable success designing semiconductor-based TV tuners. Maxlinear says its customers include wireless module makers, original equipment manufacturers and original design manufacturers.

David Rodewald, an outside spokesman for the company, said MaxLinear executives would not comment beyond the statement issued today.

The number of shares to be offered and the price range for the offering were not disclosed, although Dow Jones says the Carlsbad company plans to sell an estimated $100 million in stock. The company plans to use the proceeds for working capital and general corporate purposes.

The founders self-funded MaxLinear for the first year, and co-founder and CEO Kishore Seendripu talked about their efforts to generate revenue by taking on consulting work and other outside work during a panel discussion on bootstrapping in San Diego six months ago. Seendripu defined bootstrapping as “a self-sustaining process that proceeds without external help.”

MaxLinear secured its first round of venture funding in late 2004, after completing development of its first prototype silicon television tuner using CMOS technology. The company identifies its venture investors on its website as San Diego-based Mission Ventures, U.S. Venture Partners of Menlo Park, CA, and Battery Ventures, which has offices in Waltham, MA, and Menlo Park, CA.

Comments | Reprints | Share: